On November 30, 2020, IMPACT Therapeutics, Inc. closed the transaction. The company received $50,000,000 in its series C+ round of funding led by Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877). The transaction also included participation from Shenzhen Capital Group Co., Ltd., Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) and existing investors Lilly Asia Ventures and China Summit Capital.